Table E2. Detailed study characteristics: Risk assessment interventions

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year  Study Design  Clinical Setting, Country  Trial (if Named) | Duration of Nonpharma-Cologic Interventions for Patients | N of patients a  Duration of Entire Study From Baseline Through Follow-up | Intervention(s) and Comparator(s) | Funding Source | Brief Summary of Population | Age: Mean (SD)  Percent Female  Percent Non-White | Psychiatric Diagnoses (%) | Mean (SD) Severity of Psychiatric Symptoma-tology |
| Abderhalden et al., 20085  CRT  Psychiatric inpatient treatment facilities (private or public status NR), Switzerland | 12 weeks  Total days in treatment  Baseline (3 months)  G1: 6,074  G2: 8,449  Intervention (3 months)  G1: 7,727  G2: 10,485 | 879 (baseline) and 973 (intervention) b  92 weeks | G1: Structured Risk Assessment: Structured short-term risk assessment for every new patient twice a day during the first 3 days of hospitalization  G2: No intervention | Govern-ment | Adult patients between 18 and 65 years of age, most of which had an acute psychiatric disorder | Age  Overall: 39.5 (14.2) c  G1: 39.0 (13.1)  G2: 38.0 (14.3)  Percent female  Overall:  46.6 c  G1: 45.6  G2: 44.8  Percent non-white: NR | Organic, including symptomatic, mental disorders:  Overall: 3.3 c G1: 3.8  G2: 4.3  Disorders due to psychoactive substance use  Overall: 24.3 c G1: 26.2  G2: 24.2  Schizophrenia, schizotypal and delusional disorders  Overall: 31.0 c  G1: 33.4  G2: 35.7 Mood (affective) disorders  Overall: 16.2 c  G1: 15.5  G3: 15.3 Neurotic, stress-related and somatoform disorders, behavioral syndromes associated with physiological disturbances and physical factors  Overall: 14.3 c  G1: 14.3  G3: 11.5 | NR |

Table E2. Detailed study characteristics: Risk assessment interventions (continued)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year  Study Design  Clinical Setting, Country  Trial (if Named) | Duration of Nonpharma-Cologic Interventions for Patients | N of patients a  Duration of Entire Study From Baseline Through Follow-up | Intervention(s) and Comparator(s) | Funding Source | Brief Summary of Population | Age: Mean (SD)  Percent Female  Percent Non-White | Psychiatric Diagnoses (%) | Mean (SD) Severity of Psychiatric Symptoma-tology |
| Abderhalden et al., 20085  (continued) |  |  |  |  |  |  | Personality disorders of adult personality and behavior  Overall: 3.2 c G1: 4.0  G3: 5.0  Others d  Overall: 2.8 c  G1: 2.7  G3: 4.1 Missing  Overall: 4.9 c  G1: NR  G2: NR |  |

Table E2. Detailed study characteristics: Risk assessment interventions (continued)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year  Study Design  Clinical Setting, Country  Trial (if Named) | Duration of Nonpharma-Cologic Interventions for Patients | N of patients a  Duration of Entire Study From Baseline Through Follow-up | Intervention(s) and Comparator(s) | Funding Source | Brief Summary of Population | Age: Mean (SD)  Percent Female  Percent Non-White | Psychiatric Diagnoses (%) | Mean (SD) Severity of Psychiatric Symptoma-tology |
| van de Sande et al., 20116  CRT  Acute psychiatric wards, Netherlands | 30 weeks | 170 (baseline period over 10 weeks);  458 (intervention period over 30 weeks)  40 weeks | G1: Structured Risk Assessment (30 weeks):  (1) Daily risk assessments (5 minutes)  (2) Weekly risk assessments (15 minutes)  G2: Usual care / Treatment as usual (30 weeks) | Government | Patients admitted to acute psychiatric wards | Mean age (SD)  Overall: NR  G1: 38 (13)  G2: 40 (11)  Percent female  Overall: NR  G1: 47  G2: 46  Percent non-white  Overall: NR  G1: 31  G2: 16 | Psychotic disorder  Overall: NR  G1: 59  G2: 51  Personality disorders  Overall: NR G1: 20  G2: 5  Drug misuse first diagnosis  Overall: NR  G1: 3  G2: 3 | NR |

a Describes the entire study from baseline through post-intervention or longer-term follow-up.

b Neither the baseline nor intervention period count includes patients admitted to the five wards that preferred to introduce the study protocol of structured risk assessment without randomization.5

c In addition to arms presented in this table, overall mean based on information from five wards that preferred to introduce the study protocol of structured risk assessment without randomization.5

d Other diagnoses included mental retardation, disorders of psychological development, behavioral and emotional disorders with onset occurring in childhood and adolescence.5

CRT = cluster randomized trial; G = group; N = number; NR = not reported; RCT = randomized controlled trial; SD = standard deviation.